Objective: Lepidic growth is a noninvasive component of lung adenocarcinoma. Many adenocarcinoma cases contain coexistent lepidic and nonlepidic (invasive) components (lepidic-growth positive [Lepþ] adenocarcinoma); however, some cases comprise only nonlepidic components (lepidic-growth negative [Lep-] adenocarcinoma). The aim of this study was to investigate the biological differences between the invasive components of Lepþ and Lep-adenocarcinoma.
Lung cancer is one of the leading global causes of mortality. Adenocarcinoma, the most common histologic subtype of this disease, 1 is heterogeneous with respect to its molecular biology; clinical, pathologic, and radiologic features; and surgical approach. Adenocarcinoma is primarily classified as 1 of 5 histopathologic subtypes, including lepidic, papillary, acinar, solid, and micropapillary. It is widely accepted that adenocarcinoma cells exhibiting a lepidic growth pattern are noninvasive tumor components. 2, 3 Therefore, the prognostic importance of invasive component size, excluding the lepidic component, has gained gradual recognition. 4 Indeed, the TNM classification was drastically revised in 2016, especially in T category, and the size of the invasive component is now predominantly used to determine the T category. 2 Although the Eighth TNM classification reflects the prognosis of patients with lung cancer, many patients with stage I disease still have unfavorable prognoses. 5 This discrepancy indicates that factors other than invasive component size may influence prognosis.
The biological and morphologic characteristics of the invasive component are important determinants of cancer cell malignant potential. 6, 7 In addition to cancer cells, the invasive component comprises several stromal cell types, including macrophages, inflammatory cells, and fibroblasts. These stromal cells can interact with cancer cells and create a specific tumor microenvironment, influencing cancer cell proliferation, invasion, and metastasis. Given the influence of stromal cells on clinical tumor features, characterization of stromal cell phenotypes may improve our understanding of patient prognosis. [8] [9] [10] [11] Typical adenocarcinoma cases contain both lepidic and nonlepidic (invasive) components (lepidic-growth positive [Lepþ] adenocarcinomas). Computed tomography (CT) findings of these cases often include both ground-glass opacity (GGO) in the periphery and a solid component in the center. Conversely, some purely invasive cases, such as papillary, acinar, and solid adenocarcinoma (lepidicgrowth negative [Lep-] adenocarcinoma), typically only exhibit a solid component on CT. In clinical investigations, the presence of a GGO component may indicate a good prognosis in patients with an early clinical stage. 12 Of note, Moon and colleagues 13 reported that the lack of a lepidic component was associated with an unfavorable prognosis, even in patients with stage I. As a result, the presence of a lepidic GGO pattern in lung adenocarcinoma may confer a favorable prognosis.
We hypothesized that the tumor microenvironment of the invasive component of Lepþ adenocarcinoma would differ from that of Lep-adenocarcinoma and that this relationship would persist in lesions with size-matched invasive (nonlepidic) components. To this end, we characterized the clinicopathologic differences between the invasive components of Lepþ and Lep-invasive size-matched tumors.
MATERIALS AND METHODS Patients
A retrospective review of data from accumulated the Thoracic Surgical Database in National Cancer Center Hospital East was performed. Patients who underwent R0 resection by lobectomy or more for lung adenocarcinoma at our institution from January 2003 to December 2011 were enrolled in this study. We excluded patients who underwent preoperative treatment and patients with insufficient data. We classified them according to the pathologic status defined by the 2004 World Health Organization classification and the Eighth edition of the TNM classification of the Union for International Cancer Control. Stage IA adenocarcinomas measuring 3 cm or less (n ¼ 575) were then divided into 2 groups: Lepþ adenocarcinomas (lepidic component ratio in their tumor of !10%) and Lep-adenocarcinomas (lepidic component ratio of <10%) ( Table 1 and Figure 1 ).
All studies involving human participants were performed in accordance with the ethical standards of the institutional and national research committees, and with the 1964 Declaration of Helsinki, its later amendments, or comparable ethical standards. Comprehensive informed consent was obtained in the study.
Histopathologic Evaluation
Resected specimens were fixed with 10% formalin and embedded in paraffin, and 4-mm sections were stained with hematoxylin-eosin (HE) stain. Vascular and lymphovascular invasion were identified by HE and the Victoria blue-van Gieson, visualizing elastic fibers, staining. Histologic subtype and total and invasive size were reviewed by S.K. and G.I., and tumors were classified according to the 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. Tumor staging was based on the Eighth Edition of the TNM classification of the International Association for the Study of Lung Cancer.
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Matching of Invasive Size
We matched the invasive component sizes of selected tumors (optimal matching with no caliper) statistically using EZR (Saitama Medical Center, Jichi Medical University; see ''Statistical Methods''). Patients were allocated in a 1:1 ratio, and 2 groups with the same number of patients (n ¼ 116 per group) were selected for further analysis (Table 2) . Standardized differences of both pre-and postmatched cohort are shown in Tables 1  and 2 .
Immunohistochemical Staining
Because we predicted that the biological differences between Lep(þ) and Lep(-) adenocarcinoma would be found even in early-stage cancer, we selected 62 pathologic T1b tumors from each group of matched cases for immunohistochemical (IHC) staining. One case with variant type (showing only intrabronchial growth) in Lep-adenocarcinomas was excluded (n ¼ 62 Lepþ adenocarcinomas; n ¼ 61 Lep-adenocarcinomas). Slides were deparaffinized with xylene and dehydrated with a graded ethanol series. Endogenous peroxidase was blocked with 3% hydrogen peroxide in absolute methyl alcohol. After epitope retrieval, slides were washed with phosphate-buffered saline (PBS) and incubated overnight at 4 C with primary antibodies at their final dilution in the blocking buffer. The primary antibodies we used are shown in Table E1 . We chose cancer stem cell-related molecule (ALDH-1, CD44) because a higher expression level of cancer stem cell-related molecules was reported to be a prognostic marker and associated with a subtype of adenocarcinoma. To investigate the potential of invasiveness, proliferation, or hypoxic condition in cancer cells, we selected invasion-related molecule (laminin-5) and hypoxiarelated molecules (glucose transporter 1 [GLUT1], carbonic anhydrase [CA] IX). To research the tumor promoting stromal cells, we investigated PDPNþ cancer-associated fibroblast (CAFs) and CD204þ tumorassociated macrophages (TAMs). 11, 14, 15 Then after washing them with PBS again, they were incubated with EnVision (Agilent Technologies, Santa Clara, Calif) for 1 hour at room temperature. After washing them with PBS, the color reaction was performed with diaminobenzidine. Finally, these slides were counterstained with Meyer's hematoxylin, dehydrated, and mounted. 
Immunohistochemical Scoring Method
Two pathologists (S.K. and G.I.) independently evaluated all tissue sections using light microscopy. Noninvasive and invasive component areas were determined using HE or Victoria blue-van Gieson-stained sections. The IHC staining scores of ALDH1, CD44, CA IX, GLUT-1, and laminin-5 were evaluated on the basis of the staining intensity and the percentage, corresponding to every 10 percentages (0%-100%), of stained cancer cells. We used the following scoring system: 0 (negative staining, defined as no immunoreactivity); 1þ (weak staining intensity); 2þ (strong staining intensity). We calculated staining scores by multiplying the stained percentages by the staining intensity, ranging from 0 to 200, in each slide. We excluded 3 laminin-5-stained slides (2 Lepþ cases; 1 Lep-case) because of unsatisfactory staining. Evaluation of scoring for podoplanin (PDPN) þ CAFs was calculated on the basis of the staining intensity and the stained percentage of CAFs with the method described next. CD204þ TAMs in the stroma of the tumor-invasive component were enumerated across 3 high-power fields and averaged.
Survival Analysis
All patients were basically followed up for 5 years after surgery at least and up to 10 years. Recurrence or survival information was obtained as possible by letters in the case of patients who cannot make regular clinics visit up to 10 years. The length of overall survival was defined as the period between the date of surgery and the last follow-up date or death due to any cause. In the same way, the period of relapse-free survival was calculated in months from the date of resection to the date of first recurrence or last follow-up and death from any cause. Observations were censored at the last follow-up when the patient was alive or lost to follow-up. The data cutoff date was May 2016 at our institution.
Statistical Methods
We performed matching for patients on the basis of the invasive component size using the following algorithm: 1:1 optimal match with no caliper and no replacement. Associations between the clinicopathologic factors and the presence of lepidic growth were analyzed using the multivariate logistic regression analysis (for categoric variables) or the Mann-Whitney U test (for continuous variables). Histologic subtypes and IHC results were assessed using the Mann-Whitney U test. Overall survival (in months) was calculated from the date of resection to the More precisely, EZR is a modified version of R commander that incorporates frequently used biostatistical functions.
RESULTS

Clinicopathologic Differences Between Lepþ and Lep-Adenocarcinomas
We identified 459 Lepþ and 116 Lep-adenocarcinomas, the clinicopathologic differences between which are shown in Table 1 . No significant differences in patient age, sex distribution, preoperative serum carcinoembryonic antigen levels, or total tumor size were detected, but we did observe significant differences in the smoking history of the 2 groups. With respect to pathologic characteristics, Lepþ adenocarcinomas exhibited a smaller invasive component size (10.5 vs 19.5 mm.; P<.01) and were more likely to be early pathologic T stage (P <.01). The frequencies of both vascular and lymphovascular invasion were not significantly different between the 2 groups, whereas the frequency of epidermal growth factor receptor mutations was significantly higher in Lepþ adenocarcinomas (P <.01). Table 2 shows the clinicopathologic features of Lepþ and Lep-tumors matched for invasive component size. There were no significant differences in invasive component size or pathologic T status between the 2 groups. Most of their invasive components were composed of mixed subtypes, but the dominant subtypes in the invasive component were significantly different between the 2 groups (P<.01). Almost all of the differences of characteristics were not significant, but total tumor size was significantly greater in Lepþ adenocarcinomas (25 vs 20 mm, P <.01). Figure E1 shows the Kaplan-Meier curves for the overall and relapse-free survival of patients with Lepþ and Lepadenocarcinoma. We did not observe significant differences for both overall survival and relapse-free survival between the 2 groups. There were also no significant survival differences between Lepþ and Lep-adenocarcinomas, which were performed by using IHC staining ( Figure E2 ).
Clinicopathologic Differences of Tumors Matched for Invasive Component Size
Prognostic Impact of the Presence of Lepidic Growth
Immunohistochemical Staining Score
The IHC staining results are summarized in Tables 3  and 4 .
Evaluation of cancer cells (1) Cancer stem cell-related molecule
Cancer cell-specific ALDH1, which exhibited a cytoplasmic staining pattern, did not differ between the 2 groups. As for the staining of CD44, expressed in the membrane and cytoplasm of cancer cell, the score was significantly higher in Lepþ adenocarcinomas (50 vs 20, P < .01) ( There were no significant differences in the expression levels of laminin-5 between the 2 groups.
Evaluation of stromal cells (1) PDPNþ CAFs
The staining score for PDPNþ CAFs was significantly lower in Lepþ adenocarcinomas (0 vs 0 (mean: 1.6 vs 11.6), P <.01) (Figure 2) . (2) M2 macrophages The number of CD204þ TAMs was significantly lower in Lepþ adenocarcinomas (8.7 vs 24.7, P <.01) (Figure 2 ). 
DISCUSSION
In this study, we compared the clinicopathologic features of Lepþ and Lep-adenocarcinomas with size-matched invasive components. In survival analysis, there were no significant differences between Lepþ and Lep-adenocarcinomas. On IHC staining (Figure 3) , both hypoxia marker scores (GLUT-1 and CA IX) and scores of the tumor-promoting stromal cells (CD204þ TAMs and PDPNþ CAFs) were significantly lower in Lepþ adenocarcinomas. These results indicate that the invasive component of Lepþ, but not Lep-, adenocarcinoma is associated with a less malignant microenvironment. To our knowledge, this is the first study to clarify the clinicopathologic differences between the invasive components of Lepþ and Lep-adenocarcinomas.
GLUT-1 and CA IX are established hypoxia markers. Hypoxia is an important factor that influences tumor proliferation and malignant progression. 14, 15 Elevated expression of GLUT-1 and CA IX in solid cancers, including lung cancer, is known as a poor prognostic factor and is associated with a greater risk of vascular invasion and metastasis. [17] [18] [19] [20] [21] In our study, the expression of GLUT-1 and CA IX was significantly attenuated in Lepþ adenocarcinomas. This result indicates that the invasive component of Lepþ adenocarcinoma exhibits a reduced invasive potential. Lep(þ) adenocarcinomas had a significantly lower percentage of solid component than Lep(-) adenocarcinomas (Table E2 ). Chiu and colleagues 22 reported the strong correlation of solid growth pattern and GLUT1 expression, and this result was consistent with ours.
Compared with Lep-adenocarcinomas, Lepþ tumors contained a lower number of PDPNþ CAFs and CD204þ TAMs (M2 macrophages). Given that these stromal cells promote cancer cell invasion and tumor metastasis, [23] [24] [25] we conclude that Lepþ adenocarcinomas are associated with a less-invasive microenvironment.
By using an animal hypoxia model, Zhang and colleagues 26 reported that hypoxia significantly promotes lung cancer metastasis accompanied by an increased infiltration of M2 macrophages. In addition, Kolenda and colleagues 27 reported that with human glioma cell lines LN308 and U87MG cells, a robust increase in PDPN mRNA was observed with those in the condition of 72-hour hypoxia compared with those in the normoxic condition. Therefore, lower numbers of tumor-promoting stromal cells in Lepþ adenocarcinomas may be associated with less hypoxic conditions.
In the present study, expression levels of CD44 were significantly higher in Lepþ adenocarcinomas. CD44 expression is reportedly correlated with long survival and predominantly lepidic subtypes in lung adenocarcinoma, consistent, in part, with our results. 28 In fact, one of the supportive explanations is that the interaction between CD44 FIGURE 3. Schematic of a model for Lepþ and Lep-adenocarcinoma development. Upper: Lepþ adenocarcinomas progress slowly with preservation of the alveolar structure as stepwise progression, which can be maintained with co-opted vessels. Lower: Lep-adenocarcinomas often grow rapidly and destructively, and widespread vascular disruption and regression of co-opted vessels may occur in the invasive area, resulting in a hypoxic core. AIS, Adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; LPA, lepidic predominant adenocarcinoma. and its ligand of hyaluronic acid may inhibit angiogenesis and progression of cancers. 29 The current World Health Organization classification scheme proposes that the new adenocarcinoma in situ and minimally invasive carcinoma categories represent a stepwise progression of Lepþ adenocarcinoma. Naito and colleagues 11 reported that this morphologic progression is associated with elevated cancer cell-specific expression of invasion-related molecules, as well as increased recruitment of tumor-promoting stromal cells. Thus, Lepþ adenocarcinomas may slowly acquire malignant potential as their invasive components undergo stepwise changes (ie, ''multistage carcinogenesis'') ( Figure 3) .
On the contrary, the mechanism of Lep-adenocarcinoma tumorigenesis is poorly understood. In a process known as vessel (or vascular) co-option, tumor cells may grow adjacent to preexisting blood vessels, thereby facilitating tumor cell-mediated acquisition of oxygen and essential nutrients without obligate neovascularization. [30] [31] [32] Progression of Lepþ adenocarcinoma can be supplied with co-opted vessels, because they grow up slowly with preservation of the alveolar structure. However, Lep-adenocarcinoma often grows rapidly and destructively, leading to widespread disruption of coopted vessels and the development of a hypoxic core (Figure 3) . 32, 33 A previous study reported a strong correlation between the sizes of solid and invasive tumor components as determined by thin-section CT. 34 So, given that tumors lacking GGO on thin-section CT are likely Lep-adenocarcinomas, treatment strategies for those tumors, especially performing limited resection, must be carefully selected, and additional preoperative examination such as positron emission tomography CT may provide more information. 35 We investigated patients who underwent lobectomy, and the survival differences between the 2 groups were slight but not significant. However, the opportunity of performing limited resection for the patients with small-size tumors has been increasing, and our IHC results suggest that performing limited resection for Lep(-) adenocarcinomas may have the possibility of undertreatment. Therefore, careful patient selection will be required when we plan on performing limited resection. To clarify this hypothesis, further investigation for survival data from patients with Lep(-) adenocarcinoma who receive sublobar resection is necessary.
Study Limitations
First, this study was retrospective and conducted in a single institution. Second, in the IHC staining scoring, we could not be blinded to the presence or absence of lepidic component. Third, the associations we observed may be due to chance, so further verification in other studies will be required.
CONCLUSIONS
The current study indicated that lower levels of cancer cell-specific hypoxia marker expression and a smaller number of tumor-promoting stromal cells in the invasive component were characteristic features of Lepþ adenocarcinoma. These results suggest that the invasive component of Lepþ adenocarcinoma is associated with a less malignant tumor microenvironment. Given that Lepþ adenocarcinoma is less invasive with less metastatic potential, early-stage small Lepþ adenocarcinomas may be treated with limited resection techniques such as wide-wedge resection and segmentectomy. Further investigation based on survival data from patients with Lep(-) adenocarcinoma who receive sublobar resection will be required. 
